Drug Detail

Information about Gleevec, Sutent

Generic Name
CS-1008, imatinib or sunitinib
CS-1008, STI-571 or SU11248
Brand Name (US)
Gleevec, Sutent
Daiichi Sankyo
Drug Type
Tyrosine Kinase Inhibitor and Monoclonal antibody
Intravenous, Oral
Approval Status
CS-0118 is in phase 2 trials. A trial testing this combination was withdrawn.
Overall Strategy
KIT Protein Based
Activate death receptors + Block KIT
Drug Category
KIT/PDGFRA inhibitor + Death receptor activator

CS-1008 is an IgG1 agonistic humanized monoclonal antibody targeting the human death receptor 5 (DR5). CS- 1008 triggers apoptosis after binding to DR5 resulting in death of targeted cells; it has demonstrated cytotoxic activity against DR5-positive human tumor cell lines in vitro, and in vivo it has shown significant anti-tumor activity against human tumor xenografts in nude mice.